Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A personalized neoantigen vaccine called TG4050 kept every vaccinated patient relapse-free in a phase 1 trial for HPV-negative head and neck cancer. The vaccine was well tolerated and triggered long-lasting immune responses targeting each patient's unique tumor mutations. While the trial was too small to confirm efficacy, results are promising enough to fuel an ongoing phase 2 study.
A personalized cancer vaccine is turning heads in head and neck oncology. In a randomized phase 1 trial published in Nature Communications, adjuvant TG4050 — a viral vector–based vaccine encoding up to 30 patient-specific neoantigens — produced zero relapses among vaccinated patients with resected, HPV-negative head and neck squamous cell carcinoma (HNSCC), compared to three relapses in the observation group over a median 30-month follow-up. An updated analysis at 41 months showed no new relapses in either arm.
The vaccine was also safe and well tolerated, with no dose-limiting toxicities and no grade 3 or higher treatment-related side effects. Most adverse events were mild injection-site reactions. Neoantigen-specific immune responses were detected in nearly three-quarters of evaluable vaccinated patients, and these T-cell responses persisted for up to a year after the last dose.
By the Numbers:
Why it matters: HPV-negative HNSCC carries a high recurrence risk and limited treatment options post-surgery. A personalized vaccine that trains the immune system to recognize each patient's unique tumor fingerprint could be a game-changer — and a phase 2 trial is already underway to confirm these early signals.
